FectoVIR®-AAV

FectoVIR®-AAV represents a breakthrough synthetic transfection reagent specifically engineered for industrial-scale recombinant AAV (rAAV) production in both suspension and adherent HEK293-derived cell systems. This next-generation solution addresses critical manufacturing challenges in viral vector production through superior performance metrics and comprehensive regulatory support.

Enhanced Productivity and Cost Reduction

FectoVIR®-AAV delivers exceptional viral genome titers with up to 10-fold increases compared to standard PEI-based reagents. This remarkable performance translates directly into manufacturing economics, enabling production of significantly more doses per batch while reducing total manufacturing costs by up to 85%. The reagent's superior efficiency means fewer bioreactors are required, reducing both capital expenses and operational costs.

Industrial Scalability Solutions

Large-scale manufacturing demands are met through two key innovations. The optimized complexation volume requirement of just 1% dramatically simplifies preparation logistics – reducing complexation volumes from 200 L to 20 L for 2,000 L suspension cultures. Additionally, transfection complexes maintain stability for up to three hours after mixing, eliminating transfer time constraints that typically cause titer variability in large-scale operations.

GMP Compliance and Risk Mitigation

FectoVIR®-AAV GMP is manufactured under validated, aseptic processes in full compliance with ICH Q7 GMP Part II guidelines. The comprehensive regulatory support package includes certificates of compliance, drug master files, TSE/BSE documentation, and identity/activity testing protocols to support both IND and BLA submissions. Residual testing methods are available through qualified service providers to ensure product safety and regulatory compliance.

Versatile Application Support

The reagent supports diverse manufacturing configurations including closed-system operations through 1 L bags with MPC connections and weldable tubing to minimize contamination risks. Available in multiple formats from 1 mL research vials to 1 L GMP-grade bags, FectoVIR®-AAV scales seamlessly from development through commercial production phases.

This comprehensive solution enables biotechnology and pharmaceutical companies to optimize their rAAV manufacturing processes while maintaining the highest quality standards required for gene and cell therapy applications.